Global Viral Vector Manufacturing Market Grows at a Staggering CAGR of 19.7%

Introduction

Molecular biologists use viral vectors to introduce genetic material into cells. In order to treat genetic disorders, it is used to express and present pathogenic antigens to simulate an infection and elicit an immune response. Since it aids in treating numerous diseases, such as heart defects, metabolic diseases, and neurodegenerative disorders, it has numerous applications in life science research, gene therapy, and vaccination.

Market Dynamics

Increasing Prevalence of Cancers, Infectious Diseases, and Genetic Disorders Drives the Global Market

Cancer is most prevalent in clinical trials for gene therapy. Cancer gene therapy stops the vascularization of tumors, kills cancerous cells, and enhances the immune system's response to tumor antigens. Many acquired diseases are treated using gene and cell therapy. Viral vector production is anticipated to increase during the forecast period due to promising therapeutic results and increasing competition among leading biopharmaceutical companies to have gene therapy products approved and sold for unmet medical needs.

Favorable Government Initiatives Creates Tremendous Opportunities

Significant government initiatives are in place to advance precision and personalized medicine, bolstering the R&D efforts of businesses and academia. Direct funding from the government, increased public awareness, and changes to the regulatory environment, like accelerated approval processes, are all driving market expansion. Additionally, several companies combine, acquire, and publish products related to viral vectors. For instance, Merck revealed plans to support its Bio Reliance viral and gene therapy service by opening a second Carlsbad in the United States in April 2020.

Regional Analysis

Europe is the most significant shareholder in the global viral vector manufacturing market and is expected to grow at a CAGR of 28.37% during the forecast period. The German market for the production of viral vectors is growing due to increased R&D efforts and advantageous pharmaceutical regulations. The country also has a high rate of cancer cases and a large number of businesses involved in healthcare. The nation's major market players' recent innovations and developments in the technology used to create viral vectors have contributed to the market's growth.

North America is expected to grow at a CAGR of 26.84%, generating USD 2,232.74 million during the forecast period. The United States is anticipated to maintain a dominant position in the global viral vector manufacturing market throughout the entire forecast period as a result of the rising number of clinical studies, funding for viral vector development, the presence of significant market players, and the rising prevalence of genetic disorders, cancer, and infectious diseases. In addition, the Organization for Economic Co-operation and Development (OECD) estimated that US biotechnology companies spend 15% of their total budgets on research and development as of 2020.

Key Highlights

• The global viral vector manufacturing market was valued at USD 769.75 million in 2021. It is expected to reach USD 6,834.62 million by 2030, growing at a CAGR of 27.46% during the forecast period (2022–2030).
• Based on type, the global viral vector manufacturing market is bifurcated into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, and retroviral vectors. The adeno-associated viral vectors segment is the highest contributor to the market and is expected to grow at a CAGR of 28% during the forecast period.
• Based on disease, the global viral vector manufacturing market is bifurcated into cancer, genetic disorders, and infectious diseases. The cancer segment owns the highest market share and is expected to grow at a CAGR of 27.54% during the forecast period.
• Based on the application, the global viral vector manufacturing market is bifurcated into gene therapy and vaccinology. The gene therapy segment is the highest contributor to the market and is expected to grow at a CAGR of 26.16% during the forecast period.
• Europe is the most significant shareholder in the global viral vector manufacturing market and is expected to grow at a CAGR of 28.37% during the forecast period.

Competitive Players

Competitive Players

The global viral vector manufacturing market’s major key players are Cognate BioServices Inc. (Cobra Biologics), Finvector, Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies), Kaneka Corporation (Eurogentec), Merck KGaA, Uniqure NV, Oxford BioMedica PLC, Sanofi SA, F Hoffmann-La Roche Ltd (Spark Therapeutics), and Thermo Fisher Scientific Inc.

Recent Developments

Market News

• In September 2022, ReiThera expanded large-scale viral vector production capabilities. The new 1,500-square-meter facility was granted operational authorization from AIFA, the Italian Medicines Agency, to enable production scales of up to 3,000 liters.
• In September 2022, Oxford Biomedica Solutions LLC ("Oxford Biomedica Solutions"), a high-performing full-scope AAV manufacturing and innovation business, signed an agreement with a new undisclosed, U.S.-based, private biotechnology company. Oxford Biomedica plc ("Oxford Biomedica" or "the Company") is a leading gene and cell therapy group. The partnership agreement gives the partner access to "The Full Solution" service offering from Oxford Biomedica Solutions, which includes end-to-end capabilities for their pre-clinical gene therapy programs.

Segmentation

Global Viral Vector Manufacturing Market: Segmentation

By Type

• Adenoviral Vectors
• Adeno-associated Viral Vectors
• Lentiviral Vectors
• Retroviral Vectors
• Other Types

By Disease

• Cancer
• Genetic Disorders
• Infectious Diseases
• Other Diseases

By Applications

• Gene therapy
• Vaccinology

By Regions

• North America
• Europe
• Asia-Pacific
• South America
• The Middle East and Africa